Entrada Therapeutics (NASDAQ:TRDA) Issues Earnings Results, Beats Estimates By $0.04 EPS

Entrada Therapeutics (NASDAQ:TRDA) announced its quarterly earnings data on Thursday. The company reported ($0.94) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.98) by $0.04, FiscalAI reports. The company had revenue of $0.91 million during the quarter, compared to analyst estimates of $2.30 million. Entrada Therapeutics had a negative net margin of 3,537.73% and a negative return on equity of 57.61%.

Entrada Therapeutics Trading Up 7.5%

NASDAQ:TRDA traded up $0.34 during trading hours on Friday, reaching $4.89. The company had a trading volume of 486,475 shares, compared to its average volume of 405,978. Entrada Therapeutics has a 52 week low of $4.11 and a 52 week high of $16.45. The firm has a market cap of $190.42 million, a price-to-earnings ratio of -1.27 and a beta of -0.19. The firm’s 50 day moving average price is $5.80 and its 200-day moving average price is $8.58.

Insiders Place Their Bets

In related news, major shareholder Bioventures 2014 L.P. Mpm sold 14,569 shares of Entrada Therapeutics stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $7.06, for a total value of $102,857.14. Following the completion of the sale, the insider owned 4,318,348 shares of the company’s stock, valued at $30,487,536.88. The trade was a 0.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Bioventures 2018 L.P. Mpm sold 28,837 shares of the company’s stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $7.13, for a total transaction of $205,607.81. Following the sale, the insider directly owned 3,885,115 shares of the company’s stock, valued at $27,700,869.95. The trade was a 0.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 588,391 shares of company stock valued at $4,247,578. Company insiders own 9.49% of the company’s stock.

Analyst Upgrades and Downgrades

TRDA has been the subject of a number of research analyst reports. UBS Group reissued a “neutral” rating on shares of Entrada Therapeutics in a report on Monday, October 19th. HC Wainwright reaffirmed a “neutral” rating on shares of Entrada Therapeutics in a report on Monday, October 19th. Weiss Ratings raised Entrada Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday. Wall Street Zen downgraded Entrada Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, November 1st. Finally, Roth Capital reissued a “buy” rating and issued a $11.00 target price on shares of Entrada Therapeutics in a research report on Wednesday, August 12th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $17.75.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc (NASDAQ:TRDA) is a biotechnology company focused on developing therapeutics designed to enter cells and address diseases caused by abnormal or missing intracellular proteins. The company’s approach is based on its Endosomal Escape Vehicle (EEV) platform, which is intended to deliver therapeutic payloads into target cells while helping them escape the endosome, a cellular compartment that can limit the effectiveness of some treatments.

Entrada is developing EEV-based medicines for serious diseases, particularly genetic and neuromuscular conditions.